TBIQYR7553-Global Diabetes Drug Therapy Market Research Report 2019

                                          
Diabetes is group of metabolic disorder, often referred as diabetes mellitus, results in high blood glucose levels. Body cells use glucose as a source of energy and insulin is important for the cells to absorb this glucose. When the body cells loose the capacity to respond to the insulin or body is not capable of producing sufficient insulin, it leads to an increase in blood glucose levels in the body. This condition is referred to as diabetes. Depending on the cause of development, it is divided into three types, which includes type 1 diabetes (body loses the capacity of producing sufficient insulin), type 2 diabetes (most common and body cells do not respond to insulin) and gestational diabetes (occurs in pregnant women). Among these, type 2 diabetes is the most common type and affects over 90% of the global diabetic patients.

The global Diabetes Drug Therapy market is valued at 10000 million US$ in 2018 is expected to reach 21400 million US$ by the end of 2025, growing at a CAGR of 10.0% during 2019-2025.
This report focuses on Diabetes Drug Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Diabetes Drug Therapy market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Abbott Laboratories
    Mannkind Corporation
    Bristol Myers Squibb
    Medtronic
    AstraZeneca
    Eli Lilly and Company
    GlaxoSmithKline
    Sanofi
    Novo Nordisk
    Novartis International AG

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Glucagon-like peptide-1 (GLP-1) agonist 
    Dipeptidyl-peptidase-4 (DPP-4) inhibitors 
    Sodium glucose co-transporter 2 (SGLT2) inhibitors 
    Insulin 
    Others 

Segment by Application
    Type 1 Diabetes 
    Type 2 Diabetes 
    Gestational Diabetes 
    Impaired Glucose Tolerance and Impaired Fasting Glycaemia